About E3 ubiquitin-protein ligase RNF8
E3 ubiquitin-protein ligase RNF8 (RNF8) is a protein
from Homo sapiens identified by UniProt accession
O76064, 485 residues long.
MolForge cross-references it against 0 known binders and
123 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein ligase RNF8 |
| UniProt accession | O76064 |
| Gene | RNF8 |
| Organism | Homo sapiens |
| Length | 485 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (123)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.29
- lung adenocarcinoma · score 0.28
- glioblastoma multiforme · score 0.27
- esophageal cancer · score 0.26
- squamous cell lung carcinoma · score 0.23
- gastric adenocarcinoma · score 0.20
- mean corpuscular volume · score 0.19
- mean corpuscular hemoglobin · score 0.16
- urinary bladder cancer · score 0.14
- small cell lung carcinoma · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O76064-F1 | alphafold | PREDICTED | 75.42 | — |
Amino-acid sequence (485 residues)
MGEPGFFVTG DRAGGRSWCL RRVGMSAGWL LLEDGCEVTV GRGFGVTYQL VSKICPLMIS RNHCVLKQNP EGQWTIMDNK SLNGVWLNRA RLEPLRVYSI HQGDYIQLGV PLENKENAEY EYEVTEEDWE TIYPCLSPKN DQMIEKNKEL RTKRKFSLDE LAGPGAEGPS NLKSKINKVS CESGQPVKSQ GKGEVASTPS DNLDPKLTAL EPSKTTGAPI YPGFPKVTEV HHEQKASNSS ASQRSLQMFK VTMSRILRLK IQMQEKHEAV MNVKKQTQKG NSKKVVQMEQ ELQDLQSQLC AEQAQQQARV EQLEKTFQEE EQHLQGLEIA QGEKDLKQQL AQALQEHWAL MEELNRSKKD FEAIIQAKNK ELEQTKEEKE KMQAQKEEVL SHMNDVLENE LQCIICSEYF IEAVTLNCAH SFCSYCINEW MKRKIECPIC RKDIKSKTYS LVLDNCINKM VNNLSSEVKE RRIVLIRERK AKRLF
Explore E3 ubiquitin-protein ligase RNF8 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets